- Open Access
Alzheimer’s disease pathological lesions activate the spleen tyrosine kinase
© The Author(s). 2017
- Received: 30 August 2017
- Accepted: 30 August 2017
- Published: 6 September 2017
The pathology of Alzheimer’s disease (AD) is characterized by dystrophic neurites (DNs) surrounding extracellular Aβ-plaques, microgliosis, astrogliosis, intraneuronal tau hyperphosphorylation and aggregation. We have previously shown that inhibition of the spleen tyrosine kinase (Syk) lowers Aβ production and tau hyperphosphorylation in vitro and in vivo. Here, we demonstrate that Aβ-overexpressing Tg PS1/APPsw, Tg APPsw mice, and tau overexpressing Tg Tau P301S mice exhibit a pathological activation of Syk compared to wild-type littermates. Syk activation is occurring in a subset of microglia and is age-dependently increased in Aβ-plaque-associated dystrophic neurites of Tg PS1/APPsw and Tg APPsw mice. In Tg Tau P301S mice, a pure model of tauopathy, activated Syk occurs in neurons that show an accumulation of misfolded and hyperphosphorylated tau in the cortex and hippocampus. Interestingly, the tau pathology is exacerbated in neurons that display high levels of Syk activation supporting a role of Syk in the formation of tau pathological species in vivo. Importantly, human AD brain sections show both pathological Syk activation in DNs around Aβ deposits and in neurons immunopositive for pathological tau species recapitulating the data obtained in transgenic mouse models of AD. Additionally, we show that Syk overexpression leads to increased tau accumulation and promotes tau hyperphosphorylation at multiple epitopes in human neuron-like SH-SY5Y cells, further supporting a role of Syk in the formation of tau pathogenic species. Collectively, our data show that Syk activation occurs following Aβ deposition and the formation of tau pathological species. Given that we have previously shown that Syk activation also promotes Aβ formation and tau hyperphosphorylation, our data suggest that AD pathological lesions may be self-propagating via a Syk dependent mechanism highlighting Syk as an attractive therapeutic target for the treatment of AD.
- Alzheimer’s disease
- Spleen tyrosine Kinase
- Dystrophic neurite
- Tau hyperphosphorylation
- Tau oligomers
- Tg PS1/APPsw
- Tg APPsw
- Tg Tau P301S
Alzheimer’s disease (AD) is a neurodegenerative disease that accounts for the majority of all cases of dementia. AD pathological hallmarks include extracellular aggregates of Aβ, intracellular tau hyperphosphorylation and aggregation, as well as neuroinflammation. Tau is a microtubule-associated protein (MAP) involved in many essential cellular processes including stabilization of the microtubule network, thereby providing a functional basis for intracellular transport . Misfolding and pathological post-translational modifications including tau hyperphosphorylation contribute to its oligomerization and accumulation that ultimately leads to neuronal death . In addition, tau mutations that cause familial forms of dementia associated with the formation of tau aggregates have been identified suggesting that pathological tau species may play a key role in AD.
Tau and Aβ have been proposed to synergistically contribute to the pathobiology of AD . Through cleavage of the amyloid precursor protein (APP) by α, β and γ-secretases different variants of Aβ and soluble APP forms (α, β) are generated . A variety of post-translational modifications and the nature of the Aβ variants define their susceptibility to aggregation and neurotoxicity [41, 42]. Several mutations in the APP and presenilin (PSEN1/2) genes (members of the γ-secretase complex) have been identified and cause familial forms of AD (FAD) . These mutations either render APP more susceptible to cleavage by the β-secretase (BACE-1) or the γ-secretase resulting in increased Aβ production or lead to the production of longer forms of Aβ that are more prone to aggregation and accumulation resulting in early onset AD (EOAD). In contrast, the etiology of sporadic or late onset AD (LOAD) accounts for more than 99% of all AD cases and remains unknown .
Many studies have suggested the importance of neuroinflammation caused by Aβ in AD and that a therapeutic strategy can only be successful if it counteracts the neurotoxicity caused by inflammation [24, 29]. Aβ fibrils have been shown to trigger an inflammatory response in primary microglial and monocytic cells via an activation of the tyrosine kinases Lyn (Lck/Yes novel tyrosine kinase) and Syk (spleen tyrosine kinase) [3, 23]. Importantly, Syk inhibition appears to prevent Aβ-mediated neurotoxicity in vitro . A subsequent study also showed that Syk is the mediator of the Aβ-induced cytokine production including tumor necrosis factor alpha (TNFα) and interleukin 1 beta (IL-1β) by activated microglia  suggesting that Syk is a key kinase responsible for the proinflammatory activity of Aβ.
Many different sites of tau hyperphosphorylation have been identified in AD and various kinases have been the subject of investigations regarding their possible involvement in tau pathogenesis. Syk and Src family kinases have been shown to phosphorylate tau directly at Y18 [20, 25]. Tau tyrosine phosphorylation is considered an early pathological change in AD [5, 20]. Syk has also been shown to phosphorylate microtubules which could have an effect on microtubule polymerization or the interaction of signaling molecules with the microtubule network . Moreover, pharmacological Syk inhibition has been found to stabilize microtubules through dephosphorylation of microtubules and microtubule associated proteins (MAPs) .
We have previously shown that Syk regulates the activation of the glycogen synthase kinase-3β (GSK3β), one of the main tau kinase that phosphorylates tau at multiple sites present in neurofibrillary tangles . In addition, we have shown that Syk also regulates Aβ production and proposed that Syk could be an important therapeutic target for the treatment of AD as pharmacological inhibition of Syk appears to reduce tau hyperphosphorylation and Aβ production both in vitro and in vivo .
Syk is a non-receptor protein-tyrosine kinase (PTK) that mediates inflammatory responses . PTKs like Syk are part of receptor-mediated signal transduction cascades that require their intracellular association with integral membrane receptors including toll-like receptors (TLRs ) and Fc receptors (FcγR , FcεRI ). Recruitment and activation of Syk is also mediated by activation of triggering receptor expressed on myeloid cells 2 (TREM2) . Interestingly, several variants of TREM2 are associated with an increased risk to develop AD and have been shown to alter AD pathology including Aβ deposition, tau hyperphosphorylation, neuroinflammation and synaptic loss in AD mouse models . Syk becomes active through autophosphorylation and several Syk autophosphorylation sites have been identified in vitro: Y130, Y290, Y317, Y346, Y358, and Y525/526. The Y525/526 phosphorylation site is the main site involved in receptor-mediated Syk activation and signal propagation . Although our previous work suggests that Syk could represent a therapeutic target for AD, the cellular localization and the activity pattern of Syk in the brains of transgenic mouse models of AD and AD pathological specimens remains to be determined. We therefore investigated in this study whether Syk activation occurs in the brains of different mouse models of AD and in human AD brain by monitoring the Y525/526 Syk autophosphorylation site and analyzing its association with AD pathological hallmarks.
We investigated two different AD mouse models that overexpress APP and one mouse model of pure tauopathy that overexpresses human tau with the P301S mutation. In our study, we employed transgenic APPsw (Tg 2576) mice overexpressing the Swedish mutation (KM670/671NL) of APP695 under the control of the hamster prion protein promoter . These mice have elevated levels of Aβ and typically develop Aβ plaques at the age of 11 months . We also analyzed transgenic PS1/APPsw mice which carry the APP KM670/671NL (Swedish) and the PSEN1 M146L mutations. In these mice, the human PSEN1 M146 L transgene is driven by the PDGF-β promoter. These double transgenic mice develop cortical and hippocampal amyloid deposits at 6 months of age; much earlier than the single transgenic APPsw (Tg2576). Additionally, the total Aβ burden is increased in these double transgenic mice compared to the single Tg 2576 transgenic mice . Aβ deposits are associated with dystrophic neurites that occur at 12 months of age in Tg PS1/APPsw mice . Furthermore, these mice display an increase in Aβ plaque-associated microglia and astrocytes at 6 months of age. However, increased microglial activity has been found to occur at 12 months . In addition, we analyzed whether Syk activation occurs in the brain of transgenic Tau P301S PS19 mice that overexpress human tau with the P301S mutation. The P301S mutation in the tau gene on chromosome 17 has been associated with autosomal dominantly inherited frontotemporal dementia and parkinsonism (FTDP-17) [1, 22, 38]. The expression of the P301S mutated tau is fivefold higher in Tg Tau P301S mice than the endogenous mouse protein and is driven by the mouse prion protein promoter . Interestingly, these mice progressively develop neurodegeneration and display intraneuronal tau hyperphosphorylation and aggregation that closely mimic neurofibrillary tangles.
In this study, we show by high-resolution confocal microscopy that Syk activation is increased in a subset of activated microglia and in dystrophic neurites around Aβ plaques of Tg APPsw and Tg PS1/APPsw mice. Interestingly, pSyk is also age-dependently increased in neurons of Tg Tau P301S mice. The degree of colocalization between Syk and tau is largely dependent on the tau epitope investigated and differs between various phospho-tau epitopes and tau oligomers/conformers. The level of Syk activation, as measured by fluorescence intensity, correlates with the amount of pathological tau species detected. In addition, we show that Syk overexpression in human neuronal like cells (SH-SY5Y) results in increased total tau and tau phosphorylation levels at multiple epitopes. Taken together, our results show that β-amyloid and tau pathological species both activate Syk in vivo and conversely, that Syk is involved in microglial activation, plays a role in the pathogenesis of dystrophic neurites (DNs) and contributes to the formation of pathological tau species therefore exacerbating AD pathological lesions. Interestingly, human AD brain sections exhibit the same pattern of Syk activation as the mouse models of β-amyloidosis and tauopathy combined. Human AD brain sections show an increase in pSyk (phosphorylated Syk at Y525/526) levels in DNs around β − amyloid plaques and in neurons immunopositive for hyperphosphorylated tau (Y18) and pathological tau conformers (MC1), whereas brain sections from non-demented controls do not show any pSyk increase. Altogether, these data suggest a crucial role of Syk in the pathobiology of AD and highlight Syk as a promising therapeutic target in AD.
Tg PS1/APPsw, Tg APPsw, Tg Tau P301S and wild-type mice were generated and maintained in a C57BL/6 genetic background as previously described . All mice were maintained under specific pathogen free conditions in ventilated racks in the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited vivarium of the Roskamp Institute. All experiments involving mice were reviewed and approved by the Institutional Animal Care and Use Committee of the Roskamp Institute before implementation and were conducted in compliance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.
All mice were humanely euthanatized and their brains were collected and fixed in 4% paraformaldehyde (PFA) for 48 h. The method of euthanasia used follow the AVMA (American Veterinary Medical Association) guidelines for the euthanasia of animals. Briefly, mice were rendered unconscious through inhalation of 5% isoflurane in oxygen using a vaporizer and a gas chamber. While under anesthesia, after verifying the absence of reflexes, mice were euthanatized by exsanguination (blood was withdrawn from cardiac puncture).
Subsequently, the hemispheres were processed in a Sakura Tissue-Tek VIP (Leica Biosystems Inc., IL, USA) vacuum infiltration processor. Brains were then embedded in paraffin with the Sakura Tissue-Tek (Leica Biosystems Inc., IL, USA) and stored at 4 °C for 2 days for subsequent cutting with a Leica RM2235 microtome (Leica Biosystems Inc., IL, USA). All brains were cut at a thickness of 12 μm. Sagittal slices were mounted on glass slides and dried for 48 h at 37 °C for subsequent immunofluorescence staining and confocal imaging.
Paraffin sections were washed in two baths of histoclear (National Diagnostics, USA) and progressively rehydrated with ethanol gradients and phosphate buffered saline (PBS, Sigma Aldrich, MO, USA). Brain sections were subjected to antigen retrieval for 7 min in citric acid buffer (pH 6) at 100 °C. All sections were treated with 0.05% Sudan Black in 70% ethanol to quench autofluorescence. Sections were then blocked in PBS containing 10% donkey serum (Abcam, MA, USA) for 1 h. Sections were incubated in PBS containing 1% donkey serum and the respective panel of primary antibodies overnight at 4 °C. The following antibodies were used: CP13 (anti(α)-phospho-tau (pTau) S202, 1:200, Dr. Peter Davies’ Lab), MC1 (α-conformational tau, 1:200, Dr. Peter Davies’ Lab), TOC1 (1:200, Dr. Lester Binder’s Lab), PHF-1 (α-pTau S396/404, 1:200, Dr. Peter Davies’ Lab), 9G3 (α-pTau Y18, 1:200, MediMabs Inc., QC, Canada), DA9 (α-total-tau (tTau), 1:200, Dr. Peter Davies’ Lab), α-BACE1 (1:200 Cell Signaling, MA, USA), α-sAPPβ with Swedish mutation (1:100 Immuno-Biological Laboratories Co, Ltd., Japan), α-Iba1 (1:300, Abcam, MA, USA), α-GFAP (1:5000, Aves Labs, OR, USA), α-pSyk (Y525/526, 1:200, Cell Signaling, MA, USA). In addition to the α-pSyk (Y525/526, 1:200, Cell Signaling, MA, USA), we used the α-pSyk (Y525/526, 1:100, Abgent, CA, USA) and obtained similar results. After three washing steps in PBS for 5 min, sections were incubated in a solution containing PBS, 1% donkey serum and the respective panel of secondary antibodies for 1 h in the dark at room temperature in a humidified chamber. The following secondary antibodies were used: donkey α-rabbit, α-goat, α-mouse conjugated to Alexa 488, 568 and 647, respectively (1:500, Life technologies). After three washing steps in PBS for 5 min, sections were mounted in Fluoroshield with or without DAPI (Sigma Aldrich, MO, USA). All images were acquired using the confocal microscope LSM 800 (Carl Zeiss AG, Germany), the ZEN Blue 2.1 (Carl Zeiss AG, Germany) software and a 20× or 63× objective. The acquisition settings were kept the same for all genotypes within the same experiment.
For qualitative analysis of the pSyk burden in Tg Tau P301S mice compared to WT littermates, hippocampi and cortices of 16 male and female mice ranging from 8 to 56 weeks of age were stained and analyzed as described above.
For the quantitative analysis of the pSyk burden (Fig. 3), 140 randomly-selected microscopic fields of four non-consecutive brain slices (containing the hippocampus) from six animals per genotype (equal number of male and female) were acquired. The area covered with the pSyk immunopositive staining was quantified with Fiji  in microscopic fields containing Aβ plaques as well as in microscopic fields not containing Aβ deposits. The PS1/APPsw, APPsw and WT mice of the younger cohort were on average 45 ± 0.3 (avg. ± SEM) weeks old. The average age of the mice of the older cohort was 116 ± 13.5 weeks (±SEM). The pSyk burden of the transgenic mice was normalized to the level of pSyk burden quantified in wild-type littermates of the respective age-group. As a negative control, primary antibodies were omitted to determine background and autofluorescence (not shown).
For the quantitative analysis of the colocalization of pSyk and different tau epitopes (Fig. 8) between 400 and 570 cortical fields (50,000 μm2 per field) from four male Tg Tau P301S animals (average age 47 ± 3.1 (SEM) weeks) were analyzed for each tau epitope. To quantify the percentage of the immunopositive neurons a total of 2546 microscopic fields and 21,800 neurons were counted using the Zen Blue 2.1 software (Carl Zeiss AG, Germany).
The fluorescence intensities (Figs. 9, 10, 11, 12 and 13) of 30 to 40 neurons immunopositive for pSyk, pTau or both (colocalized) were determined for each tau epitope (total of 90 neurons per epitope) using Zen Blue 2.1 (Carl Zeiss AG, Germany). The male Tg Tau P301S mice (n = 4) used for quantification were on average 47 ± 3.1 weeks old (avg. ± SEM).
In addition, the different immunostainings mentioned above were performed on paraffin-embedded tissue sections (10 μm, dorsolateral frontal cortex) from a 67-year-old, male patient with AD (Braak VI) and a 102-year-old, male non-demented control that were provided by Dr. Ann McKee (Boston University, MA, USA). Institutional review board approval for brain donation was obtained through the Boston University Alzheimer’s Disease Center (BUADC, Boston, MA, USA).
SH-SY5Y cells were purchased from American Type Culture Collection (VA, USA). SH-SY5Y cells were grown in DMEM/F12 medium (Thermo Fisher Scientific, MA, USA) supplemented with 10% fetal bovine serum (Thermo Fisher Scientific, MA, USA), GlutaMAX and 1% penicillin/streptomycin/fungizone.
Generation of Syk overexpressing SH-SY5Y cells
A human cDNA ORF Clone of the human SYK gene (NM_003177, transcript variant 1) was purchased from OriGene Technologies (MD, USA). The cDNA fragment encoding human SYK was amplified by PCR using PfuUltra II Fusion HS DNA polymerase (Agilent Genomics, CA, USA) and subcloned into the p3xFLAG-Myc-CMV™-26 Expression Vector (Sigma-Aldrich, MO, USA) to generate the pCMV-SYK-Flag plasmid. The entire reading frame of the plasmid was confirmed by DNA sequencing. SH-SY5Y cells were maintained in advanced DMEM/F-12 medium supplemented with 10% fetal bovine serum, 1% GlutaMAX, 1% penicillin/streptomycin (Thermo Fisher Scientific, MA, USA) and incubated in a humidified 5% CO2 atmosphere at 37 °C. For stable transfection, SH-SY5Y cells were grown in 6-wells cell culture plates until reaching 70-80% confluence and transfected with 3 μg of empty pCMV vector (control cells) or pCMV-SYK-Flag plasmids per well using lipofectamine 2000 (Thermo Fisher Scientific, MA, USA). After 48 h, the medium surrounding transfected cells was replaced with fresh medium containing 0.2 mg/ml of G418 for selection. After 14 days of selection, G418 resistant cells were trypsinized and expanded. The expression efficiency of SYK was analyzed by Western blot using antibodies against SYK (4D10 Syk antibody, Santa Cruz Biotechnology, TX, USA) and the Flag tag (Sigma-Aldrich, MO, USA).
SH-SY5Y cells were cultured in 24-well-plates for 24 h and subsequently lysed with mammalian protein extraction reagent (MPER, Thermo Fisher Scientific, MA, USA) containing Halt protease & phosphatase single use inhibitor/EDTA (Thermo Fisher Scientific, MA, USA) and 1 mM PMSF. Proteins of cell lysates were separated by 10% tris-glycine-SDS-PAGE using 1 mm Criterion TGX gels (Bio-Rad Laboratories, CA, USA) and electro-transferred onto 0.2 μm PVDF membranes (Bio-Rad Laboratories, CA, USA). Membranes were blocked in TBS containing 5% non-fat dried milk for 1 h and were hybridized with the primary antibody (αSyk (4D10, 1:1000, Santa Cruz, TX, USA), αpTau S396/404 (PHF-1, 1:1000, Dr. Peter Davies’ Lab), αtTau (DA9, 1:1000, Dr. Peter Davies’ Lab), αpTau Y18 (9G3, 1:1000, MediMabs Inc., QC, Canada,) overnight at 4 °C. Subsequently, the membranes were incubated for 1 h in HRP-conjugated αmouse secondary antibody (1:1000, Cell Signaling, MA, USA). Western blots were visualized using chemiluminescence (Super Signal West Femto Maxium Sensitity Substrate, Thermo Fisher Scientific, MA, USA). Signals were quantified using ChemiDoc XRS (Bio-Rad Laboratories, CA, USA) and densitometric analyses were performed using Quantity One (Bio-Rad Laboratories, CA, USA) image analysis software.
The data were analyzed and plotted with GraphPad Prism (GraphPad Software, Inc., CA, USA). The Shapiro-Wilk test for normality was used to test for Gaussian distribution. Statistical significance was determined by either Kruskal-Wallis followed by Dunn’s post-hoc test or the non-parametric Mann–Whitney test. All data are presented as mean ± the standard error of the mean (SEM) and p < 0.05 was considered significant.
Syk activation in activated microglia and non-glial cells associated with Aβ-plaques in Tg APPsw and Tg PS1/APPsw mice
pSyk is increased in dystrophic neurites of Aβ-overexpressing mice
To further characterize the cellular origin of pSyk accumulations near Aβ plaques, we tested different markers of dystrophic neurites (BACE-1 and sAPPβ)  and found a strong colocalization between pSyk and sAPPβ (Fig. 2a) associated with Aβ deposits. The sAPPβ staining clearly reveals dystrophic swellings of neurites (Fig. 2a) which are a known hallmark of AD. Most of the dystrophic neurites are positive for pSyk (Fig. 2a). Additionally, we found a strong colocalization between sAPPβ and BACE-1 (Fig. 2b) which are often used as markers of dystrophic neurites. Both sAPPβ and BACE-1 exhibit circular accumulations near Aβ plaques (Fig. 2b), highly reminiscent of the pattern observed for activated Syk.
In conclusion, activated Syk is not only found in microglia but also in neurons near Aβ deposits, particularly in dystrophic neurites of Tg APPsw and Tg PS1/APPsw mice supporting a possible role of Syk activation in the formation of dystrophic neurites. Dystrophic neurites are characterized by an accumulation of BACE-1 and sAPPβ  and our previous work  has shown that Syk regulates BACE-1 expression and sAPPβ levels suggesting that Syk upregulation in dystrophic neurites could contribute to the accumulation of BACE-1 and sAPPβ.
Cortical pSyk burden is age-dependently increased in Aβ-overexpressing mice, particularly in microscopic fields containing Aβ-plaques, compared to wild-type littermates
The analysis of the pSyk burden in the cortex of older animals (average age: 116 weeks) revealed large differences between genotypes. The pSyk burden of Tg APPsw (216.32 ± 45.23%) mice in microscopic fields without plaques is not significantly increased compared to WT mice (100 ± 7.78%) (Fig. 3b). In contrast, microscopic fields of older Tg APPsw mice containing Aβ deposits exhibit a strong increase in pSyk burden (799.95 ± 130.19%) compared to age-matched WT mice. Tg PS1/APPsw mice also exhibit a statistically significant increase in pSyk burden in microscopic fields that do not contain Aβ deposits (458.1 ± 109.68) compared to age-matched WT controls. In addition, a much greater pSyk burden is found in Tg PS1/APPsw in microscopic fields containing Aβ deposits. In these fields, the pSyk burden is increased by 1157.31 ± 129.68% compared to WT littermates (Fig. 3b).
In conclusion, our data show that the pSyk burden is highly associated with Aβ plaques and increases with age in Tg PS1/APPsw and Tg APPsw mice whereas no activation of Syk is observed in the brain of WT littermates. The upregulation of Syk activation observed in the brains of Tg APPsw and Tg PS1/APPsw is mainly attributable to pSyk accumulations in dystrophic neurites that are associated with Aβ plaques and increase with age and Aβ burden.
Syk activity is increased in hippocampal and cortical neurons of Tg Tau P301S mice
Cortical neurons of Tg Tau P301S mice also show an increase in tau hyperphosphorylation and pSyk with age (Fig. 7). Interestingly, the onset of abnormal Syk activation occurs earlier (16 weeks of age) in the cortex than in the hippocampus (Fig. 7b compared to Fig. 6d). In conclusion, both pSyk and tau pathology in Tg Tau P301S mice increase with age but the progression is different in the hippocampus and the cortex. Many cortical neurons exhibit a colocalization of pSyk and pTau (S202) (Fig. 7b-c, e) but as mentioned earlier, there are also neurons that are singly immunopositive for pSyk or pTau.
Syk overexpression increases tau phosphorylation and total tau levels in SH-SY5Y cells
Syk activity is increased in cortical neurons immunopositive for pTau (Y18), conformationally altered Tau (MC1) and in dystrophic neurites in human AD compared to non-demented control
Our previous studies have shown that tau hyperphosphorylation, Aβ production and neuroinflammation are reduced following Syk inhibition . These data prompted us to investigate the level of Syk activation in different mouse models of AD and in brain sections from a non-demented control and an AD patient. We found that Syk activation occurs in three different mouse models of AD, overexpressing Aβ or tau, showing that Syk activation is triggered by both Aβ deposits and tau pathological species. Most importantly, we made similar observations in human AD brain sections.
Recent late phase clinical trials targeting the major pathological hallmarks of AD, mainly extracellular Aβ plaques or intra-neuronal tau aggregates, have been unsuccessful so far and have failed to prevent cognitive decline and brain atrophy in AD patients [7, 19, 37, 39]. As PET scan imaging of AD patients reveals that Aβ deposits and pathological tau accumulation occur during the prodromal phase of AD , it has been suggested that therapies that are targeting Aβ or pathological tau accumulation must be implemented decades before the appearance of the symptoms to be successful . Hence, pharmacological intervention at downstream targets of Aβ and tau may represent a more promising therapeutic strategy for AD patients. However, therapeutic targets downstream of the Aβ and tau pathological lesions remain to be identified. Our work supports the view that Syk may be such a therapeutic target as it appears to be activated in vivo in response to β-amyloidosis and the formation of pathological tau species.
In this study, we report a hyperactivation of Syk in the brains of three different AD mouse models versus wild-type/littermate controls and human AD compared to non-demented controls. In Tg PS1/APPsw, Tg APPsw mice, Syk activity is largely increased in activated microglia and in DNs around Aβ deposits. In addition, we observed an activation of Syk in DNs around Aβ deposits in an AD pathological specimen. In Tg Tau P301S mice and AD brain sections, Syk hyperactivation is colocalized with misfolded tau and hyperphosphorylated tau in neurons.
The strong increase in activated Syk observed in dystrophic neurites (DNs) surrounding Aβ deposits may suggest the involvement of Syk in the formation of these DNs that ultimately leads to the synaptic loss observed in AD . DNs are characterized by an accumulation of BACE-1 and sAPPβ which implies a contribution of DNs to Aβ production and accumulation . In fact, several in vivo studies have shown that BACE-1 immunopositive dystrophic neurites precede Aβ plaque formation in the brains of 3xTg-AD, 2xFAD and 5xFAD mice and therefore, represent an early pathological event in AD [2, 16, 45]. Our previous in vitro and in vivo data have shown that Syk regulates Aβ and sAPPβ production via a modulation of BACE-1 expression  and therefore support a causative role of Syk activation in the accumulation of BACE-1 and sAPPβ in DNs.
The increased activation of Syk in activated microglia of Aβ-overexpressing mice further supports a role of Syk in microglial activation in vivo and suggests that Aβ accumulation can lead to an activation of Syk in microglia. Previous in vitro studies have shown that Aβ fibrils and oligomers can trigger a microglial inflammatory response mediated by Syk and leading to neurotoxicity [3, 4, 23].
Recruitment and activation of Syk can also be mediated by activation of triggering receptor expressed on myeloid cells 2 (TREM2) . TREM2 is a type I transmembrane protein and part of the immunoglobulin (Ig) receptor superfamily. Since TREM2 does not have any cytoplasmic signaling motifs, an adaptor protein DNAX-activating protein of 12 kDa (DAP12, also known as TYROBP) is needed for TREM2 signal transduction. DAP12 interacts with the transmembrane domain of TREM2. The cytoplasmic domain of DAP12 contains an immunoreceptor tyrosine activation motif (ITAM) that provides docking sites for Syk activation. Interestingly, loss-of-function mutations in the DAP12 or TREM2 genes cause a rare autosomal recessive disorder called Nasu-Hakola disease (NHD) whereas heterozygous carriers of these mutations show an elevated risk to develop AD . Symptoms of NDH include multifocal bone cysts and presenile dementia. Interestingly, Syk activation (pSyk, Y525/526) is increased in NHD neurons compared to controls  and was found to be also present in microglia and macrophages but not in astrocytes or oligodendrocytes  supporting a role of Syk activation in the development of NHD dementia.
Syk plays a key role in the activation of immune cells and the production of inflammatory cytokines. We have shown previously that activation of NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells) which is known to play a regulatory role in neuroinflammation, is prevented following either pharmacological Syk inhibition or genetic knockdown of Syk . Hence, this suggests a role of Syk in the regulation of neuroinflammation. In addition, Syk has been shown to mediate the neuroinflammation and neurotoxicity caused by Aβ [3, 23]. Furthermore, the Aβ-induced cytokine production by microglia has been found to be mediated by Syk , suggesting that Syk is involved in the microglial proinflammatory response.
The pathological analysis of Tg Tau P301S mice shows that Syk activation is associated with the formation of hyperphosphorylated tau and misfolded tau in the hippocampus and cortex while our previous work has shown that Syk inhibition can reduce tau phosphorylation at multiple AD relevant epitopes . Interestingly, we show here that Syk upregulation in human neuronal like SH-SY5Y cells induces tau accumulation and tau phosphorylation further confirming a role of Syk in the formation of tau pathogenic species. Altogether, our data suggest that Syk activation may also promote tau hyperphosphorylation and misfolding in vivo as neurons that show higher levels of Syk activation also show more accumulation of hyperphosphorylated tau and tau pathogenic conformers. Pathological tau species accumulation clearly results in Syk activation in Tg Tau P301S mice while Syk activation appears to be a mediator of the formation of tau pathogenic species, thereby implying the existence of a positive feedback loop resulting in an enhanced progression of tau pathology. Given that Syk is also present in DNs which exhibit tau accumulation and tau phosphorylation [35, 40], this further supports a pathological role of Syk in the formation of DNs and ultimately synaptical loss.
Our previous in vivo and in vitro data show decreased tau phosphorylation at multiple epitopes (S396/404, S202, Y18) following Syk inhibition . Interestingly, we show here that Syk overexpression in SH-SY5Y cells increases tau phosphorylation and total tau levels (Y18, S396/404, DA9). The increase in total tau levels following Syk upregulation is not caused by an increased transcription, as tau mRNA levels do not vary between Syk overexpressing and control cells (data not shown). Therefore, increased Syk levels may lead to an increased translation or decreased degradation of tau or a combination of both. However, the molecular mechanisms responsible for the increased tau levels following Syk overexpression or decreased tau following Syk inhibition remain to be further investigated and are currently being studied in our laboratory.
In this study, we also provide evidence for an aberrant Syk activation in dystrophic neurites around Aβ deposits and in neurons immunopositive for pathological tau species in human AD brain sections further validating the data obtained with different transgenic mouse models of AD.
In conclusion, our data support a pathological role of Syk in the formation of Aβ deposits and misfolded tau and suggest additionally that reduction of Syk hyperactivity through pharmacological inhibition may be a promising therapeutic approach for the treatment of AD.
Funding for these studies was provided in part by the Department of Veterans Affairs VA Merit 1I01BX002572-(FC). We are thankful to the Roskamp Foundation for providing additional funding which helped to make this study possible. We are grateful to Dr. Peter Davies (Litwin-Zucker Center for Research on Alzheimer’s disease, Feinstein Institute, Manhasset, NY, USA) for kindly providing the PHF-1, CP13, DA9, RZ3 and MC1 antibodies. We are also thankful to Dr. Lester Binder (Department of Translational Science & Molecular Medicine, Michigan State University College of Human Medicine, Grand Rapids, MI, USA) for providing the TOC1 antibody. Finally, we are grateful to Dr. Ann McKee (Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, MA, USA) for providing tissue sections from an AD patient and a non-demented control.
Availability of data and materials
The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
All authors read and approved the final manuscript.
All the work involving mice was reviewed and approved by the Roskamp Institute Institutional Animal Care and Use Committee (IACUC) before implementation under the protocol R#073 and was conducted in compliance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Bugiani O, Murrell JR, Giaccone G et al (1999) Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol 58(6):667–677View ArticlePubMedGoogle Scholar
- Cai Y, Zhang X-M, Macklin LN et al (2012) BACE1 elevation is involved in amyloid plaque development in the triple transgenic model of Alzheimer's disease: differential Abeta antibody labeling of early-onset axon terminal pathology. Neurotox Res 21(2):160–174. doi:10.1007/s12640-011-9256-9 View ArticlePubMedGoogle Scholar
- Combs CK, Johnson DE, Cannady SB et al (1999) Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of beta-amyloid and prion proteins. J Neurosci 19(3):928–939PubMedGoogle Scholar
- Combs CK, Karlo JC, Kao SC et al (2001) Beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 21(4):1179–1188PubMedGoogle Scholar
- Derkinderen P, Scales TME, Hanger DP et al (2005) Tyrosine 394 is Phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine Kinase. J Neurosci 25(28):6584–6593. doi:10.1523/JNEUROSCI.1487-05.2005 View ArticlePubMedGoogle Scholar
- Faruki S, Geahlen RL, Asai DJ (2000) Syk-dependent phosphorylation of microtubules in activated B-lymphocytes. J Cell Sci 113(Pt 14):2557–2565PubMedGoogle Scholar
- Gauthier S, Feldman HH, Schneider LS et al (2016) Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 388(10062):2873–2884. doi:10.1016/S0140-6736(16)31275-2 View ArticlePubMedPubMed CentralGoogle Scholar
- Geahlen RL (2014) Getting Syk: spleen tyrosine kinase as a therapeutic target. Trends Pharmacol Sci 35(8):414–422. doi:10.1016/j.tips.2014.05.007 View ArticlePubMedPubMed CentralGoogle Scholar
- Gordon MN, Holcomb L, Jantzen PT et al (2002) Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol 173(2):183–195. doi:10.1006/exnr.2001.7754 View ArticlePubMedGoogle Scholar
- Guo T, Noble W, Hanger DP (2017) Roles of tau protein in health and disease. Acta Neuropathol 133(5):665–704. doi:10.1007/s00401-017-1707-9 View ArticlePubMedPubMed CentralGoogle Scholar
- Han C, Jin J, Xu S et al (2010) Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b. Nat Immunol 11(8):734–742. doi:10.1038/ni.1908 View ArticlePubMedGoogle Scholar
- Holcomb L, Gordon MN, McGowan E et al (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4(1):97–100View ArticlePubMedGoogle Scholar
- Hsiao K, Chapman P, Nilsen S et al (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274(5284):99–102View ArticlePubMedGoogle Scholar
- Huang Z-Y, Barreda DR, Worth RG et al (2006) Differential kinase requirements in human and mouse Fc-gamma receptor phagocytosis and endocytosis. J Leukoc Biol 80(6):1553–1562. doi:10.1189/jlb.0106019 View ArticlePubMedGoogle Scholar
- Irizarry MC, McNamara M, Fedorchak K et al (1997) APPSw transgenic mice develop age-related a beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 56(9):965–973View ArticlePubMedGoogle Scholar
- Kandalepas PC, Sadleir KR, Eimer WA et al (2013) The Alzheimer's beta-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol 126(3):329–352. doi:10.1007/s00401-013-1152-3 View ArticlePubMedPubMed CentralGoogle Scholar
- Kober DL, Brett TJ (2017) TREM2-Ligand interactions in health and disease. J Mol Biol 429(11):1607–1629. doi:10.1016/j.jmb.2017.04.004 View ArticlePubMedGoogle Scholar
- Lanier LL, Bakker AB (2000) The ITAM-bearing transmembrane adaptor DAP12 in lymphoid and myeloid cell function. Immunol Today 21(12):611–614. doi:10.1016/S0167-5699(00)01745-X View ArticlePubMedGoogle Scholar
- Le Couteur DG, Hunter S, Brayne C (2016) Solanezumab and the amyloid hypothesis for Alzheimer's disease. BMJ 355:i6771. doi:10.1136/bmj.i6771 View ArticlePubMedGoogle Scholar
- Lebouvier T, Scales TM, Williamson R et al (2009) The microtubule-associated protein tau is also phosphorylated on tyrosine. J Alzheimers Dis 18(1):1–9. doi:10.3233/JAD-2009-1116 View ArticlePubMedGoogle Scholar
- Lin K-C, Huang D-Y, Huang D-W et al (2016) Inhibition of AMPK through Lyn-Syk-Akt enhances FcepsilonRI signal pathways for allergic response. J Mol Med (Berl) 94(2):183–194. doi:10.1007/s00109-015-1339-2 View ArticleGoogle Scholar
- Lossos A, Reches A, Gal A et al (2003) Frontotemporal dementia and parkinsonism with the P301S tau gene mutation in a Jewish family. J Neurol 250(6):733–740. doi:10.1007/s00415-003-1074-4 View ArticlePubMedGoogle Scholar
- McDonald DR, Brunden KR, Landreth GE (1997) Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J Neurosci 17(7):2284–2294PubMedGoogle Scholar
- McGeer PL, McGeer EG (2013) The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol 126(4):479–497. doi:10.1007/s00401-013-1177-7 View ArticlePubMedGoogle Scholar
- Nisbet RM, Polanco J-C, Ittner LM et al (2015) Tau aggregation and its interplay with amyloid-beta. Acta Neuropathol 129(2):207–220. doi:10.1007/s00401-014-1371-2 View ArticlePubMedGoogle Scholar
- Ossenkoppele R, van Berckel BN, Prins ND (2011) Amyloid imaging in prodromal Alzheimer's disease. Alzheimers Res Ther 3(5):26. doi:10.1186/alzrt88 View ArticlePubMedPubMed CentralGoogle Scholar
- Paloneva J, Manninen T, Christman G et al (2002) Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet 71(3):656–662. doi:10.1086/342259 View ArticlePubMedPubMed CentralGoogle Scholar
- Paris D, Ait-Ghezala G, Bachmeier C et al (2014) The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-beta production and tau hyperphosphorylation. J Biol Chem 289(49):33927–33944. doi:10.1074/jbc.M114.608091 View ArticlePubMedPubMed CentralGoogle Scholar
- Prokop S, Miller KR, Heppner FL (2013) Microglia actions in Alzheimer’s disease. Acta Neuropathol 126(4):461–477. doi:10.1007/s00401-013-1182-x View ArticlePubMedGoogle Scholar
- Sada K, Takano T, Yanagi S et al (2001) Structure and function of Syk protein-tyrosine Kinase. J Biochem 130(2):177–186View ArticlePubMedGoogle Scholar
- Sadleir KR, Kandalepas PC, Buggia-Prevot V et al. (2016) Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Abeta generation in Alzheimer’s disease. Acta Neuropathol doi:10.1007/s00401-016-1558-9
- Sanchez-Varo R, Trujillo-Estrada L, Sanchez-Mejias E et al (2012) Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer's mice hippocampus. Acta Neuropathol 123(1):53–70. doi:10.1007/s00401-011-0896-x View ArticlePubMedGoogle Scholar
- Satoh J-I, Tabunoki H, Ishida T et al (2012) Phosphorylated Syk expression is enhanced in Nasu-Hakola disease brains. Neuropathology 32(2):149–157. doi:10.1111/j.1440-1789.2011.01256.x View ArticlePubMedGoogle Scholar
- Schindelin J, Arganda-Carreras I, Frise E et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9(7):676–682. doi:10.1038/nmeth.2019 View ArticlePubMedGoogle Scholar
- Schmidt ML, DiDario AG, Lee VM et al (1994) An extensive network of PHF tau-rich dystrophic neurites permeates neocortex and nearly all neuritic and diffuse amyloid plaques in Alzheimer disease. FEBS Lett 344(1):69–73View ArticlePubMedGoogle Scholar
- Shepherd C, McCann H, Halliday GM (2009) Variations in the neuropathology of familial Alzheimer's disease. Acta Neuropathol 118(1):37–52. doi:10.1007/s00401-009-0521-4 View ArticlePubMedGoogle Scholar
- Siemers ER, Sundell KL, Carlson C et al (2016) Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement 12(2):110–120. doi:10.1016/j.jalz.2015.06.1893 View ArticlePubMedGoogle Scholar
- Sperfeld AD, Collatz MB, Baier H et al (1999) FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. Ann Neurol 46(5):708–715View ArticlePubMedGoogle Scholar
- St-Amour I, Cicchetti F, Calon F (2016) Immunotherapies in Alzheimer’s disease: too much, too little, too late or off-target? Acta Neuropathol 131(4):481–504. doi:10.1007/s00401-015-1518-9 View ArticlePubMedGoogle Scholar
- Su JH, Cummings BJ, Cotman CW (1993) Identification and distribution of axonal dystrophic neurites in Alzheimer's disease. Brain Res 625(2):228–237View ArticlePubMedGoogle Scholar
- Thal DR, Walter J, Saido TC et al (2015) Neuropathology and biochemistry of Abeta and its aggregates in Alzheimer's disease. Acta Neuropathol 129(2):167–182. doi:10.1007/s00401-014-1375-y View ArticlePubMedGoogle Scholar
- Viola KL, Klein WL (2015) Amyloid beta oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol 129(2):183–206. doi:10.1007/s00401-015-1386-3 View ArticlePubMedPubMed CentralGoogle Scholar
- Yoshiyama Y, Higuchi M, Zhang B et al (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53(3):337–351. doi:10.1016/j.neuron.2007.01.010 View ArticlePubMedGoogle Scholar
- Yu Y, Gaillard S, Phillip JM et al (2015) Inhibition of spleen tyrosine Kinase potentiates Paclitaxel-induced Cytotoxicity in ovarian cancer cells by stabilizing microtubules. Cancer Cell 28(1):82–96. doi:10.1016/j.ccell.2015.05.009 View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang X-M, Cai Y, Xiong K et al (2009) Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development. Eur J Neurosci 30(12):2271–2283. doi:10.1111/j.1460-9568.2009.07017.x View ArticlePubMedPubMed CentralGoogle Scholar